The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases
The DOI matches its Crossref record, with a small difference in title or year; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Objective To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression. Method Outpatients with recurrent unipolar depression (DSM-IV criteria; N = 1096) were randomly assigned in a 3:1 ratio to 10 weeks of treatment with venlafaxine ER or fluoxetine. Responders (17-item Hamilton Rating Scale for Depression [HAM-D(17)] total score or= 50% decrease from baseline) entered a 6-month, double-blind continuation phase on the same medication. Continuation-phase responders were enrolled into maintenance treatment consisting of 2 consecutive 12-month phases. At the start of each maintenance phase, venlafaxine ER responders were randomly assigned to receive double-blind treatment with venlafaxine ER or placebo, and fluoxetine responders were continued for each period. The second 12-month maintenance phase compared the time to recurrence of depression with venlafaxine ER (75 to 300 mg/day) versus placebo as the primary efficacy measure. The primary definition of recurrence was a HAM-D(17) total score > 12 and Results The cumulative probabilities of recurrence through 12 months in the venlafaxine ER (N = 43) and placebo (N = 40) groups were 8.0% (95% CI = 0.0 to 16.8) and 44.8% (95% CI = 27.6 to 62.0), respectively (p Conclusion In this study, an additional 12 months of maintenance therapy with venlafaxine ER was effective in preventing recurrence of dep…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Keller 2007 (n = 83) reported that one (1/40) participant in the discontinuation group experienced suicidal ideation; study authors considered this possibly related to study treatment.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Keller 2007
In the citing paper
“No other suicide-related events in the continuation group or in the discontinuation group were reported.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Keller 2007
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
(1993) · PubMed · Cited by 1,900
Assessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782
Keller, M. B. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180050009 · Cited by 1,643
Self-citationThree-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
The inventory for depressive symptomatology (IDS): Preliminary findings
John Rush, A., Giles, D. E., Schlesser, M. A., Fulton, C. L., Weissenburger, J., & Burns, C. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90060-0 · Cited by 918
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Recurrence after recovery from major depressive disorder during 15 years of observational follow-up
Mueller, T. I., Leon, A. C., Keller, M. B., Solomon, D. A., Endicott, J., Coryell, W., Warshaw, M., & Maser, J. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1000 · Cited by 897
Self-citation
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,521
Self-citationKennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Stuck in a rut: rethinking depression and its treatment
Holtzheimer, P. E., & Mayberg, H. S. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2010.10.004 · Cited by 430
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
Segal, Z. V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., Bloch, R., & Levitan, R. D. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.168 · Cited by 429
“(%) 10 (36) 10 (39) 12 (40) Employed, No.”
Schramm, E., Klein, D. N., Elsaesser, M., Furukawa, T. A., & Domschke, K. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30099-7 · Cited by 255
Fluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 252
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
“…counts of previous depressive episodes; (f) initial weeks of treatment prior to randomization; (g) month duration of continuation or long-term trials; (h) type of antidepressant (older agents [TCAs, the atypical agents dothiepin and mianserin, or MAO inhibitors] vs. newer agents [SSRIs or…”
BackgroundComprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M. A., Sloan, D. M., & Thase, M. E. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.027 · Cited by 183
Self-citationWhy antidepressants are not antidepressants: STEP‐BD, STAR*D, and the return of neurotic depression
Nassir Ghaemi, S. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00639.x · Cited by 144
Using Bayes factors for testing hypotheses about intervention effectiveness in addictions research
Beard, E., Dienes, Z., Muirhead, C., & West, R. (2016) · Addiction · doi:10.1111/add.13501 · Cited by 132
Craighead, W. E., & Dunlop, B. W. (2014) · Annual Review of Psychology · doi:10.1146/annurev.psych.121208.131653 · Cited by 128
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M., Sloan, D. M., & Thase, M. E. (2010) · Focus · doi:10.1176/foc.8.4.foc592 · Cited by 126
Self-citationJacobs, R. H., Barba, A., Gowins, J. R., Klumpp, H., Jenkins, L. M., Mickey, B. J., Ajilore, O., Peciña, M., Sikora, M., Ryan, K. A., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291715002615 · Cited by 108
“The risk of repeated episodes increases as a function of previous episodes (Keller et al. 2007) and 70% of individuals in remission are at risk for future episodes.”
BackgroundMeta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100
McIntyre, R. S., Park, K. Y., Law, C. W. Y., Sultan, F., Adams, A., Lourenço, M. T. C., Lo, A., Soczynska, J. K., Woldeyohannes, H. O., Alsuwaidan, M. T., et al. (2010) · CNS Drugs · doi:10.2165/11533280-000000000-00000 · Cited by 115
Predicting relapse after antidepressant withdrawal – a systematic review
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017) · Psychological Medicine · doi:10.1017/s0033291716002580 · Cited by 93
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Pharmacotherapy of Mood Disorders
Thase, M. E., & Denko, T. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095301 · Cited by 79
Self-citationMachmutow, K., Meister, R., Jansen, A., Kriston, L., Watzke, B., Härter, M. C., & Liebherz, S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012855.pub2 · Cited by 65
“Keller 2007 Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the 2-year and combined maintenance phases.”
BackgroundEvidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression
Dunlop, B. W. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150042 · Cited by 112
Publication Bias and the Efficacy of Antidepressants
Mathew, S. J., & Charney, D. S. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071102 · Cited by 63
Dunlop, B. W., Li, T., Kornstein, S. G., Friedman, E. S., Rothschild, A. J., Pedersen, R., Ninan, P., Keller, M., & Trivedi, M. H. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.04.032 · Cited by 52
“The ITT population included all patients who had at least one dose of study medication and at least one postbaseline HAM-D17 evaluation (Keller et al., 2007b).”
BackgroundMethodResultInfluentialSelf-citationMöller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.08.002 · Cited by 53
“beneficial efficacy of modern antidepressants in this respect [47,81,94].”
BackgroundLanglieb, A. M., & Guico-Pabia, C. J. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.09r00826blu · Cited by 51
Correlation between patient and clinician assessments of depression severity in the PREVENT study
Dunlop, B. W., Li, T., Kornstein, S. G., Friedman, E. S., Rothschild, A. J., Pedersen, R., Ninan, P., & Keller, M. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.02.008 · Cited by 49
“After 6 months of continuation treatment, remission rates were 72% for patients in the venlafaxine ER group and 69% for fluoxetine-treated patients (Keller et al., 2007b).”
InfluentialSelf-citationThe use of antidepressants in clinical practice: focus on agomelatine
McAllister‐Williams, R. H., Baldwin, D. S., Haddad, P. M., & Bazire, S. (2010) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1094 · Cited by 48
“, 1993) and venlafaxine (Keller et al., 2007)) there was no initial separation between the placebo- and agomelatine-treated patients.”
BackgroundResultKornstein, S. G., Pedersen, R. D., Holland, P. J., Nemeroff, C. B., Rothschild, A. J., Thase, M. E., Trivedi, M. H., Ninan, P. T., & Keller, M. B. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07841 · Cited by 46
Self-citationTachyphylaxis in major depressive disorder: A review of the current state of research
Kinrys, G., Gold, A. K., Pisano, V. D., Freeman, M. P., Papakostas, G. I., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.357 · Cited by 45
A Review of Antidepressant Therapy in Primary Care: Current Practices and Future Directions
Kennedy, S. H. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01420 · Cited by 41
Studies of Long-Term Use of Antidepressants: How Should the Data from Them be Interpreted?
El-Mallakh, R. S., & Briscoe, B. (2012) · CNS Drugs · doi:10.2165/11599450-000000000-00000 · Cited by 36
Trivedi, M. H., Dunner, D. L., Kornstein, S. G., Thase, M. E., Zajecka, J. M., Rothschild, A. J., Friedman, E. S., Shelton, R. C., Keller, M. B., Kocsis, J. H., et al. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.04.011 · Cited by 36
“Previous published reports have described efficacy and safety outcomes observed in the trial, including outcomes on psychosocial measures during acute and continuation phase treatment (Keller et al., 2007a,b; Kocsis et al., 2007).”
InfluentialSelf-citationFluoxetine for adults who are overweight or obese
Serralde-Zúñiga, A. E., Garay, A. G. G., Rodríguez‐Carmona, Y., & Meléndez, G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011688.pub2 · Cited by 43
Rickels, K., Montgomery, S. A., Tourian, K. A., Guelfi, J. D., Pitrosky, B., Padmanabhan, S. K., Germain, J.-M., Leurent, C., & Brisard, C. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c94c4d · Cited by 33
Gili, M., Vicens, C., Roca, M., Andersen, P., & McMillan, D. (2014) · Preventive Medicine · doi:10.1016/j.ypmed.2014.07.035 · Cited by 35
How Should Primary Care Doctors Select Which Antidepressants to Administer?
Gartlehner, G., Thaler, K. J., Hill, S., & Hansen, R. A. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0283-x · Cited by 31
Thase, M. E., Gelenberg, A. J., Kornstein, S. G., Kocsis, J. H., Trivedi, M. H., Ninan, P. T., Li, T., Pedersen, R., & Keller, M. B. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.07.009 · Cited by 28
Self-citationSerralde-Zúñiga, A. E., Garay, A. G. G., Rodríguez‐Carmona, Y., & Meléndez, G. (2022) · Obesity Facts · doi:10.1159/000524995 · Cited by 28
Gelenberg, A. J., Dünner, D. L., Rothschild, A. J., Pedersen, R., Dorries, K. M., & Ninan, P. T. (2013) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e318288d298 · Cited by 26
“The detailed inclusion/exclusion criteria for this trial have been previously described (Keller et al., 2007a).”
BackgroundMethodResultSelf-citationMöller, H. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970903101665 · Cited by 25
“2004) by the inhibiting effect of R-citalopram at an allosteric transporter binding sector (Lepola et al. 2004; Llorca et al. 2005; Keller et al. 2007; Mallinckrodt et al. 2007; Montgomery et al. 2007; Montgomery and Möller 2009; Papakostas et al. 2007; Thase et al. 2001, 2007; Bauer et al. 2009).”
BackgroundThe Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
Self-citationDunlop, B. W., Cha, J., Choi, K. S., Nemeroff, C. B., Craighead, W. E., & Mayberg, H. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01653-w · Cited by 24
Self-citationHiguchi, T., Kamijima, K., Nakagome, K., Itamura, R., Asami, Y., Kuribayashi, K., & Imaeda, T. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000105 · Cited by 30
“In addition, the long-term efficacy of venlafaxine ER has been reported in several studies, including the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study (Montgomery et al., 2004; Simon et al., 2004; Keller et al., 2007; Kornstein et al., 2008).”
BackgroundKornstein, S. G. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.737 · Cited by 21
Self-citationGuo, Z., Chen, L., Tang, L., Gao, Y., Chand, T., Şen, Z. D., Li, M., Walter, M., Wang, L., & Liu, C. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.083 · Cited by 21
Fagiolini, A. M., Cardoner, N., Pırıldar, Ş., Ittsakul, P., Ng, B., Duailibi, K., & Hindy, N. E. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2242264 · Cited by 26
“(47.3%; 95% confidence interval [CI] 36.4, 58.2) than for venla-faxine XR (28.5%; 95% CI 18.3, 38.7); p = 0.005 [42].”
InfluentialEndicott, J., Lam, R. W. M., Hsu, M., Fayyad, R. S., Boucher, M., & Guico‐Pabia, C. J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.011 · Cited by 20
“Trivedi and colleagues (Trivedi et al., 2010) evaluated psychosocial outcomes in patients with recurrent MDD who received up to 2 years of maintenance therapy with venlafaxine extended release (ER) or placebo in the PREVENT study (Keller et al., 2007).”
BackgroundBaldessarini, R. J., Lau, W. K., Sim, J. Z. T., Sum, M. Y., & Sim, K. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw092 · Cited by 20
“…among 5 reports with flow charts to account for the dispositions of all subjects and treatments (Kornstein et al., 2006; Parahia et al., 2006; Keller et al., 2007; Kelin et al., 2010; Liebowitz et al., 2010; Rosenthal et al., 2013), rates of early loss averaged 56.6% (554/979) with…”
BackgroundInfluentialKennedy, J. C., Dunlop, B. W., Craighead, L. W., Nemeroff, C. B., Mayberg, H. S., & Craighead, W. E. (2018) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000279 · Cited by 17
Self-citationKornstein, S. G., Kocsis, J. H., Ahmed, S., Thase, M. E., Friedman, E. S., Dunlop, B. W., Yan, B., Pedersen, R., Ninan, P. T., Li, T., et al. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328314e2cb · Cited by 19
“…analysis of the PREVENT study data [i.e., year 1: venlafaxine ER: 77%; placebo: 58%; P = 0.005 (Kocsis et al., 2007); year 2: venlafaxine ER: 92%; placebo: 55%; P < 0.001 (Keller et al., 2007a); combined maintenance phase: venlafaxine ER: 71%; placebo: 53%; P = 0.005 (Keller et al., 2007a)].”
InfluentialSelf-citationWang, W., Wang, Y., Wang, F., Chen, H., Qin, X., Yang, L., Yang, X., & Yang, L. (2024) · BMC Public Health · doi:10.1186/s12889-024-18943-7 · Cited by 18
“The chronic nature of dysthymia also requires longer and more structured treatments to address the high risk of recurrence [29].”
BackgroundCommon Questions About the Pharmacologic Management of Depression in Adults.
Kovich, H., & DeJong, A. (2015) · PubMed · Cited by 24
Continuation treatment of major depressive disorder: is there a case for duloxetine?
Norman, T. R., & Olver, J. S. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s4358 · Cited by 19
Thase, M. E., Asami, Y., Wajsbrot, D., Dorries, K. M., Boucher, M., & Pappadopulos, E. A. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1255185 · Cited by 20
Self-citationDesvenlafaxine and Weight Change in Major Depressive Disorder
Tourian, K. A., Leurent, C., Graepel, J., & Ninan, P. T. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08m00746blu · Cited by 16
Self-citationAntidepressant Trial Duration Versus Duration of Real-World Use: A Systematic Analysis
Ward, W. S., Haslam, A., & Prasad, V. K. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.04.037 · Cited by 18
Recovery and subsequent recurrence in patients with recurrent major depressive disorder
Dunlop, B. W., Holland, P., Bao, W., Ninan, P. T., & Keller, M. B. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.03.002 · Cited by 15
“…We conducted a post hoc analysis on the randomized sample of 258 patients from the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) trial (Kocsis et al., 2007; Keller et al., 2007a, b), a multiphase, double-blind trial of adult outpatients with recurrent MDD.”
BackgroundMethodSelf-citationLin, C., Chung, C., Chen, L., You, C.-H., Chien, W., & Chou, P. (2019) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2019.03.004 · Cited by 16
Ballenger, J. C. (2009) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)79087-x · Cited by 14
Do antidepressants really work?
Blier, P. (2008) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0810 · Cited by 13
“In such studies, the therapeutic benefits of antidepressants are much more evident.(4) To give an analogy, would anyone base his or her opinion on the effectiveness and benefits of a weight-loss program on an observation window of 6–8 weeks? A third crucial factor for clinicians to consider when estimating the risk–be…”
BackgroundZhou, D., Lv, Z., Shi, L., Zhou, X., Lin, Q., Chen, X., Wan, L.-Y., Li, Y., Ran, L., Huang, Y., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720001610 · Cited by 14
“Additionally, three RCTs that randomized patients after the long-term maintenance phase were included in the post hoc analysis (Bialos, Giller, Jatlow, Docherty, & Harkness, 1982; Keller et al., 2007; Kupfer et al., 1992).”
BackgroundParoxetine mesylate: comparable to paroxetine hydrochloride?
Pae, C., Misra, A., Ham, B., Han, C., Patkar, A. A., & Masand, P. S. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903451708 · Cited by 12
“These trends were replicated in a number of studies regardless of using brand-name or generic drugs in controlled trials or naturalistic studies [48-50].”
BackgroundLong-Term Treatment of Mood Disorders
Nolen, W. A., & Grunze, H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00004-x · Cited by 12
Licht, R. W. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.12.009 · Cited by 11
Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02374.x · Cited by 11
Aripiprazole Joins the Family of Second-Generation Mood Stabilizers
RYBAKOWSKI, J. K. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522b · Cited by 10
McGoldrick, A., Byrne, H., & Cadogan, C. A. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01602-z · Cited by 10
Benzodiazepines Reduce Relapse and Recurrence Rates in Patients with Psychotic Depression
Shiwaku, H., Fujita, M., & Takahashi, H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061938 · Cited by 10
Best Practices in Medical Teaching
Stahl, S. M., & Davis, R. L. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511996412 · Cited by 10
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Ito, N., Sasaki, K., Hirose, E., Nagai, T., Isoda, H., & Odaguchi, H. (2021) · Gene · doi:10.1016/j.gene.2021.145920 · Cited by 7
A Case of Sodium Oxybate Treatment of Tardive Dyskinesia and Bipolar Disorder
Berner, J. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522a · Cited by 8
Traitements médicamenteux de la dépression
Agbokou, C., & Fossati, P. (2008) · La Presse Médicale · doi:10.1016/j.lpm.2008.01.012 · Cited by 10
Benefit of slow titration of paroxetine to treat depression in the elderly
Olgiati, P., Bajo, E., Serretti, A., & the C.E.A.P (Cost‐Effectiveness Analysis on Psychiatric Disorders) ‐ group (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2433 · Cited by 6
“Relapse probabilities were estimated with and without antidepressant treatment (Keller et al., 2007; Reid and Barbui, 2010).”
MethodSopi, B. B., Yonekawa, K., Russmann, S., Bernheim, J., Caselli, S., Schmied, C. M., Hammer, H., Lam, A., & Jost, C. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082792 · Cited by 5
“It is indicated for various psychiatric disorders including depression, anxiety and panic disorders, and social phobias [1–3].”
Continuation and maintenance treatments for persistent depressive disorder
Liebherz, S., Machmutow, K., Jansen, A., Meister, R., Watzke, B., Härter, M. C., & Kriston, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012855 · Cited by 6
Managing Depression in Clinical Practice
Friedman, E. S., & Anderson, I. M. (2010) · Springer eBooks · doi:10.1007/978-1-84996-465-4 · Cited by 5
Self-citationFava, G. A. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001468 · Cited by 4
Problems in determining efficacy and effectiveness of antidepressants.
Möller, H. ‐., & Fountoulakis, K. Ν. (2011) · PubMed · Cited by 3
Watanabe, K., Thase, M. E., Kikuchi, T., Tsuboi, T., Asami, Y., Pappadopulos, E. A., Zhang, M., Boucher, M., & Kornstein, S. G. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000183 · Cited by 3
“1) (Kornstein, 2006; Keller et al., 2007a).”
BackgroundMethodResultInfluentialSelf-citationPsychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_31 · Cited by 3
Laux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_414 · Cited by 2
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_67 · Cited by 3
George, M. S. (2010) · Brain stimulation · doi:10.1016/j.brs.2010.08.002 · Cited by 2
Hamamura, T., Kodama, M., & Harada, T. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522c · Cited by 2
Stratégie thérapeutique des épisodes dépressifs. Prévention du risque de récidive
Nuss, P. (2010) · L Encéphale · doi:10.1016/s0013-7006(10)70048-8 · Cited by 1
Dursun, S. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900028261 · Cited by 1
Duloxetine in the acute and continuation treatment of major depressive disorder
Bochsler, L., Olver, J. S., & Norman, T. R. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.133 · Cited by 1
Outcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · Medical psychiatry · doi:10.3109/9781420084887.002 · Cited by 1
Self-citationBOLAND, R. J., Gaud, K. G., & Keller, M. B. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch103 · Cited by 1
Self-citationLaux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-319-56015-1_414-1 · Cited by 2
Chapter 19. Venlafaxine and Desvenlafaxine
Thase, M. E. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as19 · Cited by 1
Self-citationRisk of Recurrence of Depression During Long-Term Antidepressant Treatment
Sloan, D. M., & Kornstein, S. G. (2007) · CNS Spectrums · doi:10.1017/s1092852900028200 · Cited by 1
Self-citationDepression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Schwertfeger, N., Regen, F., Szegedi, A., & Benkert, O. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_76
Continuation and maintenance treatment
Anderson, I. M. (2010) · Springer eBooks · doi:10.1007/978-1-84996-465-4_8
Jureidini, J. N., & Mintzes, B. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522e
Keller, M. B., & Kocsis, J. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522f
Self-citationRapid Improvement in Affective Information Processing After Acute Administration of Reboxetine
Thase, M. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09081199
“Yet, it is also true that depressed patients who benefit from antidepressants remain at great risk for relapse after treatment is discontinued, even after a year of continuous remission (10).”
BackgroundSelf-citation
Metadata
- Authors
- Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dunner, D. L., Hirschfeld, R. M. A., Rothschild, A. J., Ferguson, J. M., Schatzberg, A. F., Zajecka, J. M., Pedersen, R. D., Yan, B., Ahmed, S., Musgnung, J., & Ninan, P. T.
- Affiliations
- Brown University (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pennsylvania (US)
- Vanderbilt University (US)
- Virginia Commonwealth University (US)
- Emory University (US)
- University of Pittsburgh (US)
- University of Arizona (US)
- Cornell University (US)
- The University of Texas Medical Branch at Galveston (US)
- University of Massachusetts Chan Medical School (US)
- University of Utah (US)
- Stanford University (US)
- Rush University (US)
- Pfizer (United States) (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-08-15
- Volume
- 68
- Issue
- 08
- Pages
- 1246-1256
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2060878519
- Semantic Scholar
- 41481e618885fd80b216f7fc14909c72334939c9
- Cited by
- 116
- References
- 32
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 7 · 2015: 7 · 2014: 5 · 2013: 5 · 2012: 3
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- recurrent unipolar depression, depression recurrence prevention, long-term maintenance therapy, fluoxetine, antidepressant efficacy, antidepressant safety, treatment discontinuation, remission, relapse-free survival, PREVENT study, outpatients, sustained-release formulation, adverse events
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Depressive Disorder, Dizziness, Double-Blind Method, Female, Fluoxetine, Gastrointestinal Diseases, Headache, Humans, Hypertension, Male, Middle Aged, Respiratory Tract Infections, Treatment Outcome, Antidepressive Agents, Second-Generation, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.